{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Patients will be randomized (2:1 ratio) to receive dupilumab or matching placebo. After a patient', 'is randomly assigned to dupilumab or matching placebo, the dosage of dupilumab or matching', 'placebo for the patient, 200 or 100 mg SC once q2w, will be determined based on bw >30 kg or', '<30 kg, respectively.', 'Randomization will be stratified by ICS dose (medium-dose versus high-dose) and eosinophil', 'count (<300 cells/L versus >300 cells/L) at Screening, and by region.', 'A randomized patient is defined as a patient who is registered and assigned with a treatment kit', 'number from the centralized treatment allocation system, as documented from its log file.', 'A patient cannot be randomized more than once in the study.', '8.5', 'PACKAGING AND LABELING', 'Dupilumab/placebo is supplied as glass prefilled syringes packed in a patient kit box. Each glass', 'prefilled syringe and the patient kit box is labeled.', 'Packaging is in accordance with the administration schedule. The labeling is in accordance with', 'the local regulatory specifications and requirements.', '8.6', 'STORAGE CONDITIONS AND SHELF LIFE', 'All investigational products should be stored at a temperature between 2\u00b0C and 8\u00b0C in an', 'appropriate, locked room under the responsibility of the Investigator or other authorized persons', '(eg, pharmacists) in accordance with local regulations, policies, and procedures.', 'Control of IMP storage conditions, especially control of temperature (eg, refrigerated storage) and', 'information on in-use stability and instructions for handling the Sanofi compound should be', 'managed according to the rules provided by the Sponsor.', '8.7', 'RESPONSIBILITIES', 'The Investigator, the hospital pharmacist, or other personnel allowed to store and dispense the', 'IMP will be responsible for ensuring that the IMP used in the clinical trial is securely maintained', 'as specified by the Sponsor and in accordance with applicable regulatory requirements.', \"All IMP will be dispensed in accordance with the Investigator's prescription and it is the\", \"Investigator's responsibility to ensure that an accurate record of IMP issued and returned is\", 'maintained.', 'Any quality issue noticed with the receipt or use of an IMP (deficiency in condition, appearance,', 'pertaining documentation, labeling, expiration date, etc) should be promptly notified to the', 'Sponsor. Some deficiencies may be recorded through a complaint procedure.', 'Property of the Sanofi Group - strictly confidential', 'Page 55', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'A potential defect in the quality of IMP may be subject to initiation of a recall procedure by the', 'Sponsor. In this case, the Investigator will be responsible for promptly addressing any request', 'made by the Sponsor, in order to recall the IMP and eliminate potential hazards.', 'Under no circumstances will the Investigator supply IMP to a third party (except for Duties and', 'Taxes paid (DTP) shipment, for which a courier company has been approved by the Sponsor),', 'allow the IMP to be used other than as directed by this clinical trial protocol, or dispose of IMP in', 'any other manner.', '8.7.1 Treatment Accountability and Compliance', 'The Investigator or pharmacist will also keep accurate records of the quantities of the IMP', 'dispensed, used and unused. The IMP tracking log and inventory form is to be updated each time', 'investigational product is dispensed. The study monitor will periodically check the supplies of the', 'IMP held by the Investigator or pharmacist to assess accountability.', 'All medication treatment kits (whether empty or unused) are returned by the', 'parent(s)/caregiver(s)/lega guardian(s) at each visit when a treatment dispensing is planned. The', 'completed patient injection diary (returned diary (returned to the site at each visit), returned', 'treatment kit boxes and any unused prefilled syringes will be used for drug accountability', 'purposes.', 'Treatment kit number has to be recorded on the appropriate page of the e-CRF and also on the', 'IMP tracking log and inventory log form.', 'An electronic diary is used by the parent(s)/caregiver(s)/legal guardian(s) for the daily recording', 'of albuterol/salbutamol or levalbuterol/levosalbutamol reliever medication use, daily use of', 'background therapy (ie, medium-dose ICS with a second controller medication [ie, LABA,', 'LTRA, LAMA, or methylxanthines] or high-dose ICS alone or high-dose ICS with second', 'controller), and in case of an exacerbation event, recording of increased ICS dose and/or step up', 'of second controller medication. Site personnel will review and download the electronic diary data', 'at each clinic visit and will follow up with the parent(s)/caregiver(s)/legal guardian(s) accordingly.', 'The Monitoring Team in charge of the study will have to check e-CRF data comparing them with', 'the centralized treatment allocation system information, the IMP kit and IMP tracking log and', 'inventory form.', 'For non-investigational medicinal product (NIMP) not provided by the Sponsor, tracking and', 'reconciliation has to be achieved by the Investigator and must be captured in standard site', 'documents and records (eg, medical notes).', '8.7.2 Return and/or Destruction of Treatments', 'All partially used or unused treatment kits will be retrieved by the Sponsor or destroyed at study', 'site. All used prefilled syringes should be kept in a sharp container by the', 'parent(s)/caregiver(s)/legal guardian(s) and be returned to sites for destruction. No unused IMP', 'will be destructed at site unless the Sponsor provides written authorization.', 'Property of the Sanofi Group - strictly confidential', 'Page 56', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}